Naflocort (SQ 26,490) is a topical anti-inflammatory adrenocortical steroid. It was a moderately potent inhibitor of edema formation in the rat. After extended topical application, SQ 26,490 totally inhibited edema formation without appreciable production of skin atrophy, measured under identical conditions. SQ 26,490 possesses the property for a greater separation of anti-inflammatory and atrophogenic activities than comparative corticoids.

Thiphencillin is a penicillin analog patented by Abbott Laboratories as an antibacterial agent. Thiphencillin shows potent antibacterial activity against various species and genera of pathogenic bacteria.

Acedapsone (4,4′-diacetyldiaminodiphenyl sulfone) is a long-acting intramuscular repository derivative of dapsone. Acedapsone is mainly used as a depot leprostatic agent. The parent compound possesses little activity against M. leprae but is metabolized into active dapsone. Its half-life is 46 days, and that of the derived dapsone is 43 days. A 300-mg intramuscular dose maintains dapsone levels in volunteers above the inhibitory concentration for M. leprae for approximately 100 days. Microbiologic and clinical responses are somewhat slower than those for daily dapsone are. Long-term studies with acedapsone by injection five times yearly have yielded encouraging results. Acedapsone shows promise especially in regions where, or in patients in whom, long-term oral therapy is not practical.

Brofoxine is an anxiolytic, useful in the treatment of psychosis.

Nafenopin is a hypolipidemic drug. It is also a peroxisome proliferator. In rats and mice, nafenopin is a nongenotoxic hepatocarcinogen, which induces hepatic DNA synthesis and enzyme induction both in vivo and in hepatocyte cultures in vitro. Hepatic Ca2+ mobilization induced by nafenopin may play an important role in the mechanism by which nafenopin exerts its physiological as well as its tumour promotive activity upon chronic treatment with carcinogenic doses.

Tibric Acid is a sulfamoylbenzoic acid derivative patented by American multinational pharmaceutical corporation Pfizer Inc. as a hypolipidemic agent. In preclinical models, Tibric acid, given orally, was more effective than clofibrate in preventing the hyperlipemic and hypercholesteremic effects of various diets in rats. At high concentrations in vitro, Tibric acid moderately inhibited ADP- or thrombin-induced aggregation of rabbit blood platelets. In patients with severe type IV hyperlipoproteinemia and chylomicronemia, Tibric Acid lowered serum triglyceride and cholesterol values but administration of Tibric Acid to a normal subject did not affect serum lipid levels.

Piroximone is a nonglycoside, noncatecholamine inotropic agent. In animal experiments, it has been shown to increase cardiac contractility by mechanisms unrelated to any known receptor, acting mainly by inhibition of type III phosphodiesterase. Piroximone also possesses direct vasodilatory properties in the arterial and venous vascular bed. Piroximone combines well-balanced vasodilator and inotropic properties which make it very useful for the management of congestive heart failure. Piroximone had been in phase II clinical trial for the treatment of heart failure. However, this research has been discontinued.

Bolmantalate (also known as LY-38851), an anabolic steroid that was developed by Eli Lilly but was never marketed.